Global Opioid Induced Constipation OIC Drug Report Thumbnail

Global Opioid Induced Constipation OIC Drug Market by Type (Lubiprostone, Methyl Naltrexone Bromide, Naldemedine, Alvimopan, Other), By Application (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) and Region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa), Forecast To 2028

  • Report ID: PH-674
  • Author: Up Market Research
  • Rating: 4.7
  • Total Reviews: 98
  • No. Of Pages: 220
  • Format:
  • Pub. Date: 2021-03-01
  • Share:

The Global Opioid-Induced Constipation OIC Drug Market size is forecast to grow from USD 3.1 billion in 2019 to USD 4.5 billion by 2028, at a CAGR of 6.2% during the forecast period (2021-2028). Global market growth is primarily driven by the rising prevalence of chronic pain and opioid addiction due to increased usage or abuse of prescription opioids with an increased risk for constipation as a side effect. Other factors driving this market include technological advancements in formulary development, increasing expenditure on chronic pain management therapies, and an increase in demand for non-opioid drugs (e.g., Lubiprostone) used for the treatment of constipation caused by opioid use disorder are also contributing to the growth of this market over the forecast period.

 

Opioid-Induced Constipation OIC Drugs helps in treating the problems related to bowel movements when opioids such as morphine, codeine, and hydrocodone are taken for pain relief or cough suppression.

 

On the basis of Types, the market is segmented into Lubiprostone, Methyl Naltrexone Bromide, Naldemedine, Alvimopan, and Other.

 

Lubiprostone:

Lubiprostone can be defined as a small molecule drug that is approved for the treatment of chronic idiopathic constipation and to increase the frequency in patients with opioid-induced bowel dysfunction (OIBD). The clinical efficacy of Lubiprostone has been demonstrated by its ability to treat chronic idiopathic constipation, which is a condition characterized by the less frequent passage of stool than normal.

Lubiprostone is a drug that can be used to treat chronic constipation. It works by causing the muscles in the intestines to contract, thereby speeding the passage of stool through the gut.

 

Methyl Naltrexone Bromide:

Methyl Naltrexone Bromide is an opioid antagonist that belongs to the benzomorphan family of drugs. It works by blocking opiate receptors in the brain and gastrointestinal tract, thereby reducing constipation.

Methyl Naltrexone Bromide is used to treat opioid-induced constipation (OIC) in adults who are taking long-term opioids for the treatment of chronic pain. It can also be given as a single dose before surgery, or after an overdose, when bowel function may be slowed down due to using other drugs that could cause constipation and affect recovery from anesthesia.

 

Naldemedine:

Naldemedine is an opioid antagonist used to treat opioid-induced constipation. It binds to the mu receptor and blocks signals for pain relief in those receptors, which can cause a laxative effect. Naldemedine blocks opiate receptors in the intestine and can relieve uncomfortable digestive tract symptoms caused by the long-term use of opioids without disrupting pleasurable effects like pain relief from these medications.

 

Alvimopan:

Alvimopan is a medication that treats opioid-induced constipation (OIC) by decreasing the amount of time it takes for food to move through your digestive system. It does this by acting on receptors in the intestines and colon, which sends signals telling them when contract. This helps increase peristalsis, or muscle movement, so bowel movements will be more frequent after taking Alvimopan.

 

On the basis of Application, the market is segmented into Hospital Pharmacies, Retail Pharmacies, and Online pharmacies. In hospitals, Opioid-Induced Constipation OIC Drugs are used by healthcare practitioners for treating constipation in patients who have been taking opioids. Medical professionals give these drugs to reduce the risks of opioid withdrawal symptoms and discomfort that are associated with chronic use or abrupt discontinuation of opioids.

 

On the basis of Region, the market is segmented into North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. The Latin American region has been witnessing high demand for opioids due to the increased number of opioid-induced constipation OICs launches. The popularity of such products is largely attributed to their ability to provide relief from chronic pain associated with diseases like cancer or HIV/AIDS etc., which also results in better uptake at retail pharmacies.

 

Growth Factors For The Global Opioid-Induced Constipation OIC Drug Market:

The global opioid-induced constipation OIC market is influenced by various factors. The growth of the world population, which has led to an increase in chronic diseases and noncommunicable diseases (NCDs), will contribute significantly towards driving this market. This includes a rise in cancer cases globally, where patients are more likely develop severe bouts of diarrhea due to opioids.

Oncology drugs have also been used for treatment-related side effects such as nausea and vomiting; however, these can cause constipation among other things when not administered properly. Despite its associations with pain relief, there are some instances where individuals may be prescribed a combination of opioids and narcotics manage their adverse reactions from chemotherapy or post-surgical complications like acute bowel obstruction that leads them to develop opioid-induced constipation.

 


Up Market Research published a new report titled “Opioid Induced Constipation OIC Drug Market research report which is segmented by Types (Lubiprostone, Methyl Naltrexone Bromide, Naldemedine, Alvimopan, Other), By Applications (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Players/Companies Ironwood Pharmaceuticals, Daiichi Sankyo Co, Pfizer, Progenics Pharmaceuticals, Shionogi &, Allergan, Nektar Therapeutics, Purdue Pharma, S.L.A. Pharma, Mundipharma International Limited, Ono Pharmaceutical, Takeda Pharmaceutical Company Limited, Theravance Biopharma, Bausch Health, Cosmo Pharmaceuticals SA, Daewoong Pharmaceutical, C.B. Fleet Company, Sucampo Pharmaceuticals”. 

 

Report Scope

Report Attributes Report Details
Report Title Opioid Induced Constipation OIC Drug Market Research Report
By Type Lubiprostone, Methyl Naltrexone Bromide, Naldemedine, Alvimopan, Other
By Application Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
By Companies Ironwood Pharmaceuticals, Daiichi Sankyo Co, Pfizer, Progenics Pharmaceuticals, Shionogi &, Allergan, Nektar Therapeutics, Purdue Pharma, S.L.A. Pharma, Mundipharma International Limited, Ono Pharmaceutical, Takeda Pharmaceutical Company Limited, Theravance Biopharma, Bausch Health, Cosmo Pharmaceuticals SA, Daewoong Pharmaceutical, C.B. Fleet Company, Sucampo Pharmaceuticals
Regions Covered North America, Europe, APAC, Latin America, MEA
Base Year 2020
Historical Year 2018 to 2019 (Data from 2010 can be provided as per availability)
Forecast Year 2028
Number of Pages 220
Number of Tables & Figures 154
Customization Available Yes, the report can be customized as per your need.
 

The report covers comprehensive data on emerging trends, market drivers, growth opportunities, and restraints that can change the market dynamics of the industry. It provides an in-depth analysis of the market segments which include products, applications, and competitor analysis.


Global Opioid Induced Constipation OIC Drug Industry Outlook
 

Global Opioid Induced Constipation OIC Drug Market Report Segments:

The market is segmented by Type Lubiprostone, Methyl Naltrexone Bromide, Naldemedine, Alvimopan, Other and By Application Hospital Pharmacies, Retail Pharmacies, Online Pharmacies.

 

Some of the companies that are profiled in this report are:

  1. Ironwood Pharmaceuticals
  2. Daiichi Sankyo Co
  3. Pfizer
  4. Progenics Pharmaceuticals
  5. Shionogi &
  6. Allergan
  7. Nektar Therapeutics
  8. Purdue Pharma
  9. S.L.A. Pharma
  10. Mundipharma International Limited
  11. Ono Pharmaceutical
  12. Takeda Pharmaceutical Company Limited
  13. Theravance Biopharma
  14. Bausch Health
  15. Cosmo Pharmaceuticals SA
  16. Daewoong Pharmaceutical
  17. C.B. Fleet Company
  18. Sucampo Pharmaceuticals
 

Opioid Induced Constipation OIC Drug Market research report delivers a close watch on leading competitors with strategic analysis, micro and macro market trend and scenarios, pricing analysis and a holistic overview of the market situations in the forecast period. It is a professional and a detailed report focusing on primary and secondary drivers, market share, leading segments and geographical analysis. Further, key players, major collaborations, merger & acquisitions along with trending innovation and business policies are reviewed in the report.

 

Key Benefits for Industry Participants & Stakeholders:

  • Industry drivers, restraints, and opportunities covered in the study
  • Neutral perspective on the market performance
  • Recent industry trends and developments
  • Competitive landscape & strategies of key players
  • Potential & niche segments and regions exhibiting promising growth covered
  • Historical, current, and projected market size, in terms of value
  • In-depth analysis of the Opioid Induced Constipation OIC Drug Market
 

Overview of the regional outlook of the Opioid Induced Constipation OIC Drug Market:

Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa (MEA). North America region is further bifurcated into countries such as U.S., and Canada. The Europe region is further categorized into U.K., France, Germany, Italy, Spain, Russia, and Rest of Europe. Asia Pacific is further segmented into China, Japan, South Korea, India, Australia, South East Asia, and Rest of Asia Pacific. Latin America region is further segmented into Brazil, Mexico, and Rest of Latin America, and the MEA region is further divided into GCC, Turkey, South Africa, and Rest of MEA.


Opioid Induced Constipation OIC Drug Market Overview
 

Highlights of The Opioid Induced Constipation OIC Drug Market Report:

  1. The market structure and projections for the coming years.
  2. Drivers, restraints, opportunities, and current trends of Opioid Induced Constipation OIC Drug Market.
  3. Historical data and forecast.
  4. Estimations for the forecast period 2028.
  5. Developments and trends in the market.
  6. By Type:

                1. Lubiprostone

                2. Methyl Naltrexone Bromide

                3. Naldemedine

                4. Alvimopan

                5. Other

       7. By Application:

                1. Hospital Pharmacies

                2. Retail Pharmacies

                3. Online Pharmacies

  1. Market scenario by region, sub-region, and country.
  2. Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
  3. Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
  4. Government Policies, Macro & Micro economic factors are also included in the report.
 

We have studied the Opioid Induced Constipation OIC Drug Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2028.

 

How you may use our products:

  • Correctly Positioning New Products
  • Market Entry Strategies
  • Business Expansion Strategies
  • Consumer Insights
  • Understanding Competition Scenario
  • Product & Brand Management
  • Channel & Customer Management
  • Identifying Appropriate Advertising Appeals

Opioid Induced Constipation OIC Drug Market Statistics
 

Reasons to Purchase the Opioid Induced Constipation OIC Drug Market Report:

  • The report includes a plethora of information such as market dynamics scenario and opportunities during the forecast period
  • Segments and sub-segments include quantitative, qualitative, value (USD Million,) and volume (Units Million) data.
  • Regional, sub-regional, and country level data includes the demand and supply forces along with their influence on the market.
  • The competitive landscape comprises share of key players, new developments, and strategies in the last three years.
  • Comprehensive companies offering products, relevant financial information, recent developments, SWOT analysis, and strategies by these players.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Opioid Induced Constipation OIC Drug Market Overview
   4.1 Introduction 
      4.1.1 Market Taxonomy 
      4.1.2 Market Definition 
      4.1.3 Macro-Economic Factors Impacting the Market Growth 
   4.2 Opioid Induced Constipation OIC Drug Market Dynamics 
      4.2.1 Market Drivers 
      4.2.2 Market Restraints 
      4.2.3 Market Opportunity 
   4.3 Opioid Induced Constipation OIC Drug Market - Supply Chain Analysis 
      4.3.1 List of Key Suppliers 
      4.3.2 List of Key Distributors 
      4.3.3 List of Key Consumers 
   4.4 Key Forces Shaping the Opioid Induced Constipation OIC Drug Market 
      4.4.1 Bargaining Power of Suppliers 
      4.4.2 Bargaining Power of Buyers 
      4.4.3 Threat of Substitution 
      4.4.4 Threat of New Entrants 
      4.4.5 Competitive Rivalry 
   4.5 Global Opioid Induced Constipation OIC Drug Market Size & Forecast, 2018-2028 
      4.5.1 Opioid Induced Constipation OIC Drug Market Size and Y-o-Y Growth 
      4.5.2 Opioid Induced Constipation OIC Drug Market Absolute $ Opportunity 


Chapter 5 Global Opioid Induced Constipation OIC Drug Market Analysis and Forecast by Type
   5.1 Introduction
      5.1.1 Key Market Trends & Growth Opportunities by Type
      5.1.2 Basis Point Share (BPS) Analysis by Type
      5.1.3 Absolute $ Opportunity Assessment by Type
   5.2 Opioid Induced Constipation OIC Drug Market Size Forecast by Type
      5.2.1 Lubiprostone
      5.2.2 Methyl Naltrexone Bromide
      5.2.3 Naldemedine
      5.2.4 Alvimopan
      5.2.5 Other
   5.3 Market Attractiveness Analysis by Type

Chapter 6 Global Opioid Induced Constipation OIC Drug Market Analysis and Forecast by Applications
   6.1 Introduction
      6.1.1 Key Market Trends & Growth Opportunities by Applications
      6.1.2 Basis Point Share (BPS) Analysis by Applications
      6.1.3 Absolute $ Opportunity Assessment by Applications
   6.2 Opioid Induced Constipation OIC Drug Market Size Forecast by Applications
      6.2.1 Hospital Pharmacies
      6.2.2 Retail Pharmacies
      6.2.3 Online Pharmacies
   6.3 Market Attractiveness Analysis by Applications

Chapter 7 Global Opioid Induced Constipation OIC Drug Market Analysis and Forecast by Region
   7.1 Introduction
      7.1.1 Key Market Trends & Growth Opportunities by Region
      7.1.2 Basis Point Share (BPS) Analysis by Region
      7.1.3 Absolute $ Opportunity Assessment by Region
   7.2 Opioid Induced Constipation OIC Drug Market Size Forecast by Region
      7.2.1 North America
      7.2.2 Europe
      7.2.3 Asia Pacific
      7.2.4 Latin America
      7.2.5 Middle East & Africa (MEA)
   7.3 Market Attractiveness Analysis by Region

Chapter 8 Coronavirus Disease (COVID-19) Impact 
   8.1 Introduction 
   8.2 Current & Future Impact Analysis 
   8.3 Economic Impact Analysis 
   8.4 Government Policies 
   8.5 Investment Scenario

Chapter 9 North America Opioid Induced Constipation OIC Drug Analysis and Forecast
   9.1 Introduction
   9.2 North America Opioid Induced Constipation OIC Drug Market Size Forecast by Country
      9.2.1 U.S.
      9.2.2 Canada
   9.3 Basis Point Share (BPS) Analysis by Country
   9.4 Absolute $ Opportunity Assessment by Country
   9.5 Market Attractiveness Analysis by Country
   9.6 North America Opioid Induced Constipation OIC Drug Market Size Forecast by Type
      9.6.1 Lubiprostone
      9.6.2 Methyl Naltrexone Bromide
      9.6.3 Naldemedine
      9.6.4 Alvimopan
      9.6.5 Other
   9.7 Basis Point Share (BPS) Analysis by Type 
   9.8 Absolute $ Opportunity Assessment by Type 
   9.9 Market Attractiveness Analysis by Type
   9.10 North America Opioid Induced Constipation OIC Drug Market Size Forecast by Applications
      9.10.1 Hospital Pharmacies
      9.10.2 Retail Pharmacies
      9.10.3 Online Pharmacies
   9.11 Basis Point Share (BPS) Analysis by Applications 
   9.12 Absolute $ Opportunity Assessment by Applications 
   9.13 Market Attractiveness Analysis by Applications

Chapter 10 Europe Opioid Induced Constipation OIC Drug Analysis and Forecast
   10.1 Introduction
   10.2 Europe Opioid Induced Constipation OIC Drug Market Size Forecast by Country
      10.2.1 Germany
      10.2.2 France
      10.2.3 Italy
      10.2.4 U.K.
      10.2.5 Spain
      10.2.6 Russia
      10.2.7 Rest of Europe
   10.3 Basis Point Share (BPS) Analysis by Country
   10.4 Absolute $ Opportunity Assessment by Country
   10.5 Market Attractiveness Analysis by Country
   10.6 Europe Opioid Induced Constipation OIC Drug Market Size Forecast by Type
      10.6.1 Lubiprostone
      10.6.2 Methyl Naltrexone Bromide
      10.6.3 Naldemedine
      10.6.4 Alvimopan
      10.6.5 Other
   10.7 Basis Point Share (BPS) Analysis by Type 
   10.8 Absolute $ Opportunity Assessment by Type 
   10.9 Market Attractiveness Analysis by Type
   10.10 Europe Opioid Induced Constipation OIC Drug Market Size Forecast by Applications
      10.10.1 Hospital Pharmacies
      10.10.2 Retail Pharmacies
      10.10.3 Online Pharmacies
   10.11 Basis Point Share (BPS) Analysis by Applications 
   10.12 Absolute $ Opportunity Assessment by Applications 
   10.13 Market Attractiveness Analysis by Applications

Chapter 11 Asia Pacific Opioid Induced Constipation OIC Drug Analysis and Forecast
   11.1 Introduction
   11.2 Asia Pacific Opioid Induced Constipation OIC Drug Market Size Forecast by Country
      11.2.1 China
      11.2.2 Japan
      11.2.3 South Korea
      11.2.4 India
      11.2.5 Australia
      11.2.6 South East Asia (SEA)
      11.2.7 Rest of Asia Pacific (APAC)
   11.3 Basis Point Share (BPS) Analysis by Country
   11.4 Absolute $ Opportunity Assessment by Country
   11.5 Market Attractiveness Analysis by Country
   11.6 Asia Pacific Opioid Induced Constipation OIC Drug Market Size Forecast by Type
      11.6.1 Lubiprostone
      11.6.2 Methyl Naltrexone Bromide
      11.6.3 Naldemedine
      11.6.4 Alvimopan
      11.6.5 Other
   11.7 Basis Point Share (BPS) Analysis by Type 
   11.8 Absolute $ Opportunity Assessment by Type 
   11.9 Market Attractiveness Analysis by Type
   11.10 Asia Pacific Opioid Induced Constipation OIC Drug Market Size Forecast by Applications
      11.10.1 Hospital Pharmacies
      11.10.2 Retail Pharmacies
      11.10.3 Online Pharmacies
   11.11 Basis Point Share (BPS) Analysis by Applications 
   11.12 Absolute $ Opportunity Assessment by Applications 
   11.13 Market Attractiveness Analysis by Applications

Chapter 12 Latin America Opioid Induced Constipation OIC Drug Analysis and Forecast
   12.1 Introduction
   12.2 Latin America Opioid Induced Constipation OIC Drug Market Size Forecast by Country
      12.2.1 Brazil
      12.2.2 Mexico
      12.2.3 Rest of Latin America (LATAM)
   12.3 Basis Point Share (BPS) Analysis by Country
   12.4 Absolute $ Opportunity Assessment by Country
   12.5 Market Attractiveness Analysis by Country
   12.6 Latin America Opioid Induced Constipation OIC Drug Market Size Forecast by Type
      12.6.1 Lubiprostone
      12.6.2 Methyl Naltrexone Bromide
      12.6.3 Naldemedine
      12.6.4 Alvimopan
      12.6.5 Other
   12.7 Basis Point Share (BPS) Analysis by Type 
   12.8 Absolute $ Opportunity Assessment by Type 
   12.9 Market Attractiveness Analysis by Type
   12.10 Latin America Opioid Induced Constipation OIC Drug Market Size Forecast by Applications
      12.10.1 Hospital Pharmacies
      12.10.2 Retail Pharmacies
      12.10.3 Online Pharmacies
   12.11 Basis Point Share (BPS) Analysis by Applications 
   12.12 Absolute $ Opportunity Assessment by Applications 
   12.13 Market Attractiveness Analysis by Applications

Chapter 13 Middle East & Africa (MEA) Opioid Induced Constipation OIC Drug Analysis and Forecast
   13.1 Introduction
   13.2 Middle East & Africa (MEA) Opioid Induced Constipation OIC Drug Market Size Forecast by Country
      13.2.1 Saudi Arabia
      13.2.2 South Africa
      13.2.3 UAE
      13.2.4 Rest of Middle East & Africa (MEA)
   13.3 Basis Point Share (BPS) Analysis by Country
   13.4 Absolute $ Opportunity Assessment by Country
   13.5 Market Attractiveness Analysis by Country
   13.6 Middle East & Africa (MEA) Opioid Induced Constipation OIC Drug Market Size Forecast by Type
      13.6.1 Lubiprostone
      13.6.2 Methyl Naltrexone Bromide
      13.6.3 Naldemedine
      13.6.4 Alvimopan
      13.6.5 Other
   13.7 Basis Point Share (BPS) Analysis by Type 
   13.8 Absolute $ Opportunity Assessment by Type 
   13.9 Market Attractiveness Analysis by Type
   13.10 Middle East & Africa (MEA) Opioid Induced Constipation OIC Drug Market Size Forecast by Applications
      13.10.1 Hospital Pharmacies
      13.10.2 Retail Pharmacies
      13.10.3 Online Pharmacies
   13.11 Basis Point Share (BPS) Analysis by Applications 
   13.12 Absolute $ Opportunity Assessment by Applications 
   13.13 Market Attractiveness Analysis by Applications

Chapter 14 Competition Landscape 
   14.1 Opioid Induced Constipation OIC Drug Market: Competitive Dashboard
   14.2 Global Opioid Induced Constipation OIC Drug Market: Market Share Analysis, 2019
   14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy) 
      14.3.1 Ironwood Pharmaceuticals
      14.3.2 Daiichi Sankyo Co
      14.3.3 Pfizer
      14.3.4 Progenics Pharmaceuticals
      14.3.5 Shionogi &
      14.3.6 Allergan
      14.3.7 Nektar Therapeutics
      14.3.8 Purdue Pharma
      14.3.9 S.L.A. Pharma
      14.3.10 Mundipharma International Limited
      14.3.11 Ono Pharmaceutical
      14.3.12 Takeda Pharmaceutical Company Limited
      14.3.13 Theravance Biopharma
      14.3.14 Bausch Health
      14.3.15 Cosmo Pharmaceuticals SA
      14.3.16 Daewoong Pharmaceutical
      14.3.17 C.B. Fleet Company
      14.3.18 Sucampo Pharmaceuticals
Segments Covered in the Report
The global Opioid Induced Constipation OIC Drug market has been segmented based on

By Types
  • Lubiprostone
  • Methyl Naltrexone Bromide
  • Naldemedine
  • Alvimopan
  • Other
By Applications
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
Regions
  • Asia Pacific
  • North America
  • Latin America
  • Europe
  • Middle East & Africa
Key Players
  • Ironwood Pharmaceuticals
  • Daiichi Sankyo Co
  • Pfizer
  • Progenics Pharmaceuticals
  • Shionogi &
  • Allergan
  • Nektar Therapeutics
  • Purdue Pharma
  • S.L.A. Pharma
  • Mundipharma International Limited
  • Ono Pharmaceutical
  • Takeda Pharmaceutical Company Limited
  • Theravance Biopharma
  • Bausch Health
  • Cosmo Pharmaceuticals SA
  • Daewoong Pharmaceutical
  • C.B. Fleet Company
  • Sucampo Pharmaceuticals

Buy Report